Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study
Norio Okada, Shintaro Iwama, Takayuki Okuji et al. · British Journal of Cancer · 2020
BACKGROUND: Anti-programmed cell death-1 (PD-1) antibodies can cause thyroid dysfunction. However, no predictive biomarkers enabling stratification of thyroid dysfunction risk have been identified. METHODS: A total of 209 patients treated with an anti-PD-1 antibody were evaluated for anti-thyroid antibodies at baseline and prospectively for thyroid function every 6 weeks for 24 weeks after treatment initiation, and then observed until the visits stopped. Thyroid ultrasonography was performed if the patient was positive for anti-thyroid antibodies at baseline. RESULTS: Of the 209 patients, 19 (9.1%) developed thyroid dysfunction (destructive thyroiditis or hypothyroidism). The cumulative incidence of thyroid dysfunction was significantly higher in patients who were positive vs. negative for anti-thyroid antibodies (15/44 [34.1%] vs. 4/165 [2.4%], p < 0.001). Forty-two patients positive for anti-thyroid antibodies at baseline were divided into two groups according to the presence of an irregular echo pattern. The cumulative incidence of thyroid dysfunction was significantly higher in those with an irregular vs. a regular echo pattern (13/23 [56.5%] vs. 1/19 [5.3%], p = 0.001). None of the patients developed thyroid dysfunction after the initial 24-week period. CONCLUSIONS: The risk of thyroid dysfunction induced by anti-PD-1 antibodies can be predicted by evaluation of anti-thyroid antibodies and the thyroid echo pattern at baseline. TRIAL REGISTRATION: UMIN000019024.
Cited by 77 works. doi:10.1038/s41416-020-0736-7 Open-access PDF
Authors
- Shintaro Iwama
- Takayuki Okuji
- Tomoko Kobayashi
- Eri Wada
- Takeshi Onoue
- Motomitsu Goto
- Mariko Sugiyama
- Taku Tsunekawa
- Hiroshi Takagi
- Daisuke Hagiwara
- Yoshihiro Ito
- Hidetaka Suga
- Ryoichi Banno
- Tetsunari Hase
- Masahiro Morise
- Mitsuro Kanda
- Kenji Yokota
- Naozumi Hashimoto
References
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
- Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
- Chronic Autoimmune Thyroiditis